<DOC>
	<DOCNO>NCT01060163</DOCNO>
	<brief_summary>The use platelet aggregation inhibitor , include aspirin clopidogrel ( CPDG ) , become standard management strategy patient acute coronary syndrome . On background , increase percentage patient present surgical coronary revascularization subject irreversible platelet inhibition . Investigations effect antiplatelet treatment postoperative bleeding cardiac surgery show patient treated antiplatelet agent surgery increase postoperative bleeding , also increase need transfusion blood product . As result antiplatelet effect clopidogrel , frequency serious bleed complication increase significantly , see patient require coronary artery bypass grafting ( CABG ) , especially receive clopidogrel surgery . Tranexamic acid ( TA ) widely use antifibrinolytic agent , promise substitute aprotinin latter secede 2007.The release plasmin cardiopulmonary bypass ( CPB ) activate fibrinolysis may contribute platelet dysfunction . Pharmacological inhibition fibrinolytic system may therefore ameliorate platelet dysfunction fibrinolysis CPB decrease postoperative bleeding . Tranexamic acid prevents plasmin formation inhibits fibrinolysis . Concerning cessation aprotinin increase proportion patient persistence clopidogrel surgery , evolutional work expect , especially eastern population . The purpose study assess effect tranexamic acid patient clopidogrel asprin ingestion surgery . The investigator work hypothesis tranexamic acid would lower postoperative blood loss transfusion requirement patient would attenuate bleed complication antiplatelet therapy .</brief_summary>
	<brief_title>Tranexamic Acid Clopidogrel Exposure Decrease Hemorrhage Transfusion</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Patients require primary isolated coronary artery bypass graft cardiopulmonary bypass history cardiac surgery hematocrit &lt; 33 % platelet count &lt; 100,000/ml allergy tranexamic acid recruit study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Clopidogrel</keyword>
	<keyword>Tranexamic Acid</keyword>
	<keyword>Cardiac Surgical Procedures</keyword>
	<keyword>Hemostasis</keyword>
</DOC>